Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

hereditary gastric cancer News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A recent study published in PubMed highlights global trends in gastric cancer burden among adolescents and young adults, utilizing GBD 2021 data. This observational research provides valuable insights into the epidemiology of gastric cancer in younger populations.

A case report highlights the underestimation of subserosal invasion in early gastric cancer resembling advanced gastric carcinoma with focal enteroblastic differentiation. This finding may impact diagnostic approaches and treatment strategies for gastric cancer.

A new study discusses postoperative adjuvant treatment decisions for early Epstein-Barr virus-associated gastric cancer. This research may influence treatment protocols and improve patient outcomes in this specific cancer type.

A recent study published in PubMed highlights long-term outcomes of a function-preserving strategy using non-exposure laparoscopic endoscopic cooperative surgery (LECS) for gastric cancer. This approach emphasizes selective nodal assessment, potentially improving patient quality of life.

A recent study highlights the unfavorable outcomes associated with T3N0 remnant gastric cancer following distal gastrectomy. This research underscores the need for improved management strategies for patients with this specific cancer type.

Recent research highlights the potential of Zolbetuximab in treating gastric and gastroesophageal junction cancers by targeting claudin 18.2. This study outlines the drug's mechanism and its implications for future therapies.

Not rare diseases news,news about your rare disease.